AWE
BPMC

Avidian Wealth Enterprises’s Blueprint Medicines BPMC Stock Holding History

Avidian Wealth Enterprises’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-19,000
Closed -$2.13M – 369
2020
Q4 		$2.13M Buy
+19,000
New +$2M 0.2% 75

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Avidian Wealth Enterprises's BPMC Position: Q1 2021 in Review

Avidian Wealth Enterprises sold out of Blueprint Medicines (BPMC) in Q1 2021, closing a stake of 19,000 shares — an estimated $2.13M sold.

Avidian Wealth Enterprises first reported a position in BPMC in Q4 2020 and held it in 1 quarter. The position peaked at $2.13M in Q4 2020. 263 funds tracked by Wall St. Rank hold BPMC as of Q1 2021.

  • Avidian Wealth Enterprises reported no remaining Blueprint Medicines position as of Q1 2021 after selling out during the quarter.
  • Avidian Wealth Enterprises sold 19,000 Blueprint Medicines shares in Q1 2021, an estimated $2.13M.
  • Avidian Wealth Enterprises first reported a position in Blueprint Medicines in Q4 2020 and held it in 1 quarter.
  • Avidian Wealth Enterprises's Blueprint Medicines position peaked at $2.13M in Q4 2020.
  • 263 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2021.

Based on Avidian Wealth Enterprises's 13F filing for Q1 2021, filed 5 May 2021.